Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback